<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189969</url>
  </required_header>
  <id_info>
    <org_study_id>POX-ELS-001</org_study_id>
    <nct_id>NCT00189969</nct_id>
  </id_info>
  <brief_title>Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects</brief_title>
  <official_title>Phase I Study to Evaluate Take Rate, Immunogenicity and Safety of Bavarian Nordic's Smallpox Vaccine Elstree-BN Administered to Healthy Vaccinia-Naive Subjects in the Age of 18-32 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bavarian Nordic</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the take rate (formation of a typical postvaccinal&#xD;
      lesion)and the safety and immunogenicity of the smallpox vaccine Elstree-BN.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date>February 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of a typical pock (&quot;take&quot;) which is associated historically with protection against variola within one week after vaccination.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence, relationship and intensity of any serious adverse event at any time during the study / any non-serious adverse event within 4 weeks after vaccination.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA / Neutralisation assay specific seroconversion rates and geometric mean titres 2,4,12,52 and 104 weeks after vaccination.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferone-gamma producing T cells 2,4,12,52 and 104 weeks after vaccination.</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Smallpox</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Elstree-BN</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Free of obvious health problems&#xD;
&#xD;
          -  Negative HIV test&#xD;
&#xD;
          -  Negative hepatitis B surface antigen and negative antibody to hepatitis C virus&#xD;
&#xD;
          -  Hematocrit â‰¥ 38%; white blood cells between 4.0 and 10.0 / nl with differential blood&#xD;
             count without clinical finding; and platelets between 150 and 400 / nl&#xD;
&#xD;
          -  ALT &lt; 1.5 times institutional upper limit of normal&#xD;
&#xD;
          -  Negative urine glucose by dipstick or urinalysis&#xD;
&#xD;
          -  Adequate renal function defined as a serum creatinine &lt; 1.5 mg/dL; urine protein &lt; 100&#xD;
             mg/dL or &lt; 2+ proteinuria; and a calculated creatinine clearance &gt; 55 mL/min.&#xD;
&#xD;
          -  For women, negative pregnancy test at screening and within 24 hours prior to&#xD;
             vaccination.&#xD;
&#xD;
          -  If the volunteer is female and of childbearing potential, she agrees to use acceptable&#xD;
             contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Known or suspected history of smallpox vaccination&#xD;
&#xD;
          -  Typical vaccinia scar&#xD;
&#xD;
          -  Vaccinia specific antibodies at screening&#xD;
&#xD;
          -  History of immunodeficiency&#xD;
&#xD;
          -  Known or suspected impairment of immunologic function&#xD;
&#xD;
          -  Use of immunosuppressive medication or radiation therapy&#xD;
&#xD;
          -  Any history of atopic disease&#xD;
&#xD;
          -  Eczema of any degree or history of eczema&#xD;
&#xD;
          -  Chronic exfoliative skin disorders/conditions or any acute skin disorders of large&#xD;
             magnitude&#xD;
&#xD;
          -  Any malignancy including leukemia or lymphoma&#xD;
&#xD;
          -  Presence of any infectious disease or a history or evidence of autoimmune disease&#xD;
&#xD;
          -  History or clinical manifestation of clinically significant mental illness or&#xD;
             haematological, renal, hepatic, pulmonary, central nervous, cardiovascular or&#xD;
             gastrointestinal disorders&#xD;
&#xD;
          -  History of drug or chemical abuse&#xD;
&#xD;
          -  Administration of inactivated vaccine 14 days prior to vaccination&#xD;
&#xD;
          -  Any immune modifying therapy within 4 weeks prior to vaccination&#xD;
&#xD;
          -  Administration of live attenuated vaccines within 60 days prior to vaccination&#xD;
&#xD;
          -  Receipt of blood products or immunoglobulin in the past 6 months&#xD;
&#xD;
          -  Subjects with acute febrile illness within one week prior to vaccination or subjects&#xD;
             who may be in the incubation period of an infectious disease&#xD;
&#xD;
          -  Household contacts/sexual contacts with, or occupational exposure to any of the&#xD;
             following:&#xD;
&#xD;
               1. Pregnant women&#xD;
&#xD;
               2. Children &lt;12 months of age&#xD;
&#xD;
               3. People with current or history of atopic dermatitis&#xD;
&#xD;
               4. People with chronic exfoliative skin disorders/conditions or any acute skin&#xD;
                  disorders&#xD;
&#xD;
               5. People with immunodeficiency disease, malignancies or use of immunosuppressive&#xD;
                  medications&#xD;
&#xD;
          -  History of anaphylaxis or severe allergic reaction&#xD;
&#xD;
          -  Hypersensitivity to egg or chick protein&#xD;
&#xD;
          -  Known allergies to any component of the vaccine or its diluent&#xD;
&#xD;
          -  Known allergies to any known component of VIG&#xD;
&#xD;
          -  Known allergies to cidofovir or probenecid&#xD;
&#xD;
          -  Abnormalities suggestive of any underlying disease, detected at routine tests prior to&#xD;
             study inclusion&#xD;
&#xD;
          -  Use of any investigational or non-registered drug or vaccine starting 30 days&#xD;
             preceding the study vaccine and ending at conclusion visit&#xD;
&#xD;
          -  History of myocardial infarction, angina, congestive heart failure, cardiomyopathy,&#xD;
             stroke or transient ischemic attack, or other heart condition under the care of a&#xD;
             doctor.&#xD;
&#xD;
          -  Three or more of the following risk factors: An immediate family member who has had&#xD;
             onset of ischemic heart disease before age 50 years, elevated blood pressure, elevated&#xD;
             blood cholesterol, diabetes or nicotine abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>32 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Schroedter, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Focus Clinical Drug Development GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Focus Clinical Drug Development GmbH</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein</state>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2006</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>April 20, 2006</last_update_submitted>
  <last_update_submitted_qc>April 20, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccinia</mesh_term>
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

